Skip to content
MarketScale
‹ Back to IndustriesSciences

Technologies and Developments in New Space Propulsion: Challenges, Viewpoints, and Strategies

Space is more than just a billionaire’s race: it’s a domain of exploration fostering technological innovation in the commercial space industry. Today, there are over 10,000 space-focused start-ups in the world all striving to break through with different technologies, visions, and goals. What sets some apart from others, however, are the unique partnerships and innovative…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · New Space PropulsionOuter SpaceSoftinwaySpace Industry
Share

Key takeaways

01

Space is more than just a billionaire’s race: it’s a domain of exploration fostering technological innovation in the commercial space industry.

02

Today, there are over 10,000 space-focused start-ups in the world all striving to break through with different technologies, visions, and goals.

03

What sets some apart from others, however, are the unique partnerships and innovative…

Space is more than just a billionaire’s race: it’s a domain of exploration fostering technological innovation in the commercial space industry. Today, there are over 10,000 space-focused start-ups in the world all striving to break through with different technologies, visions, and goals. What sets some apart from others, however, are the unique partnerships and innovative technological designs aimed at taking space propulsion to the next level – literally.

In this episode of The Vaya Space Podcast, host Michelle Dawn Mooney, speaks with guests Rob Fabian, Chief Operations Officer (COO) of Vaya Space, and Valentine Moroz, COO of SoftInWay Inc. about the challenges facing New Space Propulsion, as well as viewpoints, and strategies on the future of the technology.

The three discuss:

  • How leasing software from SoftInWay has grown into a new, innovative partnership within the field
  • Everything you should know about propulsion in today’s landscape
  • Exciting new technologies were created during the development of the project

Fabian explained, “I think a lot of what we’re seeing in the industry today, certainly what we’re seeing at Vaya Space, is an outgrowth in new technologies that have come out to support the underlying process…we’re doing additive manufacture of turbo pumps, of injectors, of our fuel grains themselves, it’s an integral part to how our vortex hybrid engine works but that speed of design…I think it’s a game changer for the entire industry not just for Vaya Space.”

On the challenges facing the industry, Moroz remarked, “I see other challenges, the challenges, in my opinion, are two, maybe three types of challenges, two technological and the third one is not. First of all, you know, seeing [the] success of companies like Blue Origin and SpaceX, feels like a lot of young engineers just assume that it’s really easy and you can just reprint everything and it will work, but that’s not the reality.”

Fabian has been in the air and space industry for over thirty years, first starting his career in the United States Air Force before retiring at the rank of Colonel in 2013. He worked for BAE Systems as a program manager, then held several senior leadership positions at Rocket Crafters, Inc. In addition to his role as COO at Vaya, Fabian serves as an Executive Board Member for the Space Coast Consortium Apprenticeship Program. He’s a proud graduate of the U.S. Air Force Academy, with a Bachelor’s in Space Operations, and holds his MPA from the University of Oklahoma, as well as a Master of Arts in National Security and Strategic Studies from the U.S. Naval War College.

Moroz earned his B.S. in Business Management with a focus on entrepreneurship, computational finance, and quantitative analysis from Babson College. Moroz has over eighteen years of experience in engineering and risk management. He began his career in analytics and macro research with notable work as a risk Analyst for K2 Advisors. Afterward, Moroz founded Bluefront Capital, LLC. Today, Moroz is currently the COO of SoftinWay and a specialist in Turbomachinery Technologies.

About the author

S
Sciences

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences